Literature DB >> 3884413

Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs.

J Simard, F Labrie.   

Abstract

Estrogens increase both basal and LHRH-induced LH release in rat anterior pituitary cells in culture. Following 48 h of preincubation with 1 nM 17 beta-estradiol, the maximal LH response to LHRH is increased 1.5-fold while the ED50 value of LHRH action is decreased 2.5-fold from 500 to 200 pM. The maximal 3-fold stimulation of 0.3 nM LHRH-induced LH release by 17 beta-estradiol is exerted at a KD value of 14.4 pM. Keoxifene (300 nM) completely blocks the potent stimulatory effect of 17 beta-estradiol up to 1 nM, the highest concentration of the estrogen used. As shown by the complete reversal of the stimulatory effect of 0.1 and 1.0 nM 17 beta-estradiol by keoxifene at IC50 values of 7.7 and 34 nM respectively, the antiestrogen interacts competitively with 17 beta-estradiol at the estrogen binding site. When present alone, keoxifene shows no estrogenic activity. The present data show that keoxifene acts as a pure antiestrogen on the control of LHRH-induced LH release in rat pituitary gonadotrophs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884413     DOI: 10.1016/0303-7207(85)90131-5

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

Review 1.  Raloxifene.

Authors:  J A Balfour; K L Goa
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

2.  Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.

Authors:  R Poulin; Y Merand; D Poirier; C Levesque; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872

3.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Authors:  R Poulin; D Baker; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

Review 4.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.